Woodline Partners LP Sells 26,470 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Woodline Partners LP has reduced its stake in Arcturus Therapeutics by 3.3%, now holding 780,442 shares valued at approximately $8.27 million.
• Several institutional investors have increased their holdings, with GAMMA Investing LLC raising its position by 3,482.9% in the first quarter.
• Arcturus Therapeutics reported quarterly earnings showing a significant revenue of $28.30 million, surpassing analyst expectations, and had a consensus rating of "Buy" with an average target price of $50.57.

Woodline Partners LP decreased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 780,442 shares of the biotechnology company's stock after selling 26,470 shares during the period. Woodline Partners LP owned 2.88% of Arcturus Therapeutics worth $8,265,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Invesco Ltd. increased its stake in shares of Arcturus Therapeutics by 83.1% in the first quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company's stock valued at $370,000 after buying an additional 15,836 shares during the period. Deutsche Bank AG increased its stake in shares of Arcturus Therapeutics by 42.7% in the fourth quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company's stock valued at $420,000 after buying an additional 7,417 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at about $244,000. Jacobs Levy Equity Management Inc. increased its stake in shares of Arcturus Therapeutics by 20.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company's stock valued at $1,526,000 after buying an additional 24,583 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Arcturus Therapeutics by 3,482.9% in the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after buying an additional 5,085 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Stock Up 0.1%

NASDAQ:ARCT traded up $0.02 on Wednesday, hitting $18.11. The stock had a trading volume of 153,776 shares, compared to its average volume of 474,177. The business's fifty day moving average is $15.56 and its 200 day moving average is $13.42. The company has a market cap of $491.73 million, a PE ratio of -8.11 and a beta of 2.39. Arcturus Therapeutics Holdings Inc. has a 52 week low of $8.04 and a 52 week high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.The company had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Equities analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on ARCT. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Leerink Partners cut their target price on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research report on Friday, August 22nd. HC Wainwright began coverage on Arcturus Therapeutics in a research report on Thursday, September 4th. They set a "buy" rating and a $60.00 target price on the stock. Finally, Scotiabank restated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $50.57.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.